CytomX

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. 

CEO
Sean A. McCarthy
CEOSean A. McCarthy
Employees
69
Employees69
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2010
Founded2010
Employees
69
Employees69

CTMX Key Statistics

Market cap
819.65M
Market cap819.65M
Price-Earnings ratio
-10.42
Price-Earnings ratio-10.42
Dividend yield
Dividend yield
Average volume
3.14M
Average volume3.14M
High today
$3.82
High today$3.82
Low today
$3.70
Low today$3.70
Open price
$3.80
Open price$3.80
Volume
985.14K
Volume985.14K
52 Week high
$8.21
52 Week high$8.21
52 Week low
$1.72
52 Week low$1.72

Stock Snapshot

The current CytomX(CTMX) stock price is $3.77, with a market capitalization of 819.65M. The stock trades at a price-to-earnings (P/E) ratio of -10.42.

During the trading session on 2026-05-14, CytomX(CTMX) shares reached a daily high of $3.82 and a low of $3.70. At a current price of $3.77, the stock is +1.8% higher than the low and still -1.4% under the high.

Trading volume for CytomX(CTMX) stock has reached 985.14K, versus its average volume of 3.14M.

The stock's 52-week range extends from a low of $1.72 to a high of $8.21.

The stock's 52-week range extends from a low of $1.72 to a high of $8.21.

CTMX News

TipRanks 5d
CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability

CytomX Therapeutics Inc. (CTMX) has disclosed a new risk, in the Innovation / R&D category. Unlock hedge fund-level data and powerful investing tools for smart...

TipRanks 6d
CytomX Earnings Call Highlights Varseta-M Momentum

CytomX Therapeutics Inc. ((CTMX)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level dat...

The Motley Fool 6d
CytomX Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, May 7, 2026 at 5 p.m. ET CALL PARTICIPANTS Chairman & Chief Executive Officer — Sean McCarthy Chief Financial Officer...

CytomX Q1 2026 Earnings Transcript

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More CTMX News

TipRanks 7d
CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)

Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the mu...

People also own

Based on the portfolios of people who own CTMX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.